, Columnist
Theranos’ Fatal Flaws Were in Plain Sight
With this many red flags, it’s a wonder the collapse didn’t come sooner.
Fine idea, but the execution was a bit off.
Photographer: CNBC/NBCUniversal/Getty ImagesThis article is for subscribers only.
Last week, I previewed 10 books I want to tackle during the summer reading season. I finished the first one, “Bad Blood: Secrets and Lies in a Silicon Valley Startup” by Pulitzer-Prize winning reporter John Carreyrou, over the holiday weekend. It tells the story of blood-testing startup Theranos Inc., which at one point had a value north of $9 billion — making it one of the biggest so-called unicorns in the world. Today it is essentially worthless.